samedan logo
 
 
 
spacer
home > ebr > autumn 2016 > in the genes
PUBLICATIONS
European Biopharmaceutical Review

In the Genes

Many people take pleasure in knowing that the phrase “D’oh” originates from the TV series ‘The Simpsons’, whereas those who really know smugly attribute it to Jimmy Finlayson from the Laurel and Hardy films of the 1920s and 1930s. In much the same way, many people think that stem cells and gene-editing are also new inventions. Indeed, if one were to anthropomorphise two of the newest biotechnology tools, most people would regard stem cell technology as a junior-school prodigy, and its younger brother, gene-editing, as a precocious preschooler.

This year, 2016, does indeed mark the tenth anniversary of the first description of pluripotent stem cells induced from mammalian adult fibroblast cultures by defined factors – and fewer than four years ago, a programmable, dual-RNA-guided DNA endonuclease called Cas9 caught the imagination of thousands of laboratories across the globe. Variants of these tools have enjoyed a long and successful history, winning Nobel prizes and saving lives long before their current incarnations were even a glint in their inventors’ eyes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patrick Harrison is a Molecular Biologist at University College Cork, and his research is sponsored by the Cystic Fibrosis Trust. He began using gene-editing as a research tool for rare diseases in 2005, and his group was the first to publish a gene-editing strategy to correct the most common CF mutation in cells using ZFNs. His lab is currently using CRISPR-Cas9 and Cpf1 to study CF and other rare diseases, including cystinosis and epidermolysis bullosa.
spacer
Patrick Harrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Joining forces against SARS-CoV-2

Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
More info >>

White Papers

Another Successful Visit Against the Odds

Medical Research Network (MRN) Limited

Our dedicated team of nurses, couriers and project managers deliver, come rain or shine. Making sure a Clinical Trial visit can go ahead in the home can be a complex process, and last month bad weather nearly stopped play on an important Home Trial Support visit. Thanks to the commitment and dedication from the entire team it went ahead against the odds.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement